Loading...
•
Sep 30, 2021
Ligand Q3 2021 Earnings Report
Reported financial results for the third quarter of 2021 and provided an operating forecast and program updates.
Key Takeaways
Ligand Pharmaceuticals reported excellent third quarter financial results, with total revenues of $64.8 million compared to $41.8 million for the same period in 2020. The company's core royalties tied to Kyprolis and Evomela continue to grow, and they have seen five approvals during the last year for new products or major markets that are now launching and are expected to fuel royalty growth next year and beyond.
Total revenues for Q3 2021 were $64.8 million, compared to $41.8 million for the same period in 2020.
Royalties for Q3 2021 were $15.6 million, compared to $9.0 million for the same period in 2020.
Captisol sales were $35.1 million for Q3 2021, compared to $23.4 million for the same period in 2020, primarily due to higher sales of Captisol for use with remdesivir.
Net income for Q3 2021 was $13.7 million, or $0.80 per diluted share, compared with net loss of $(6.7) million, or $(0.42) per share, for the same period in 2020.
Revenue by Segment
Forward Guidance
Ligand is reaffirming 2021 financial guidance.
Positive Outlook
- Full-year 2021 total revenues to be between $265 million and $275 million
- Adjusted earnings per diluted share to be between $5.80 and $6.05
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...